Home Press Releases

Claritas Pharmaceuticals (formerly Kalytera Therapeutics) to Focus on Development of R-107 as a Therapy for Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections

SAN FRANCISCO, CA and TORONTO, ON — (March 1, 2021) – Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.), (TSX VENTURE EXCHANGE: KLY and OTC: KALTF) (the “Company” or “Claritas“) today announced that the Company will focus its resources primarily on development of its nitric oxide-releasing compound, R-107, for the treatment of vaccine-resistant COVID-19, and other viral infections.

Continue reading Claritas Pharmaceuticals (formerly Kalytera Therapeutics) to Focus on Development of R-107 as a Therapy for Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections →

Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

SAN FRANCISCO, CA and TORONTO, ON — (January 4, 2022) – Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas“) today outlined the Company’s plans for developing R-107, the Company’s nitric oxide-releasing compound, for multiple clinical indications.

Continue reading Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries →

Claritas (formerly Kalytera Therapeutics, Inc.) to Collaborate with Salzman Group and Other Companies to Accelerate Development of R-107 for Treatment of Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections

SAN FRANCISCO, CA and TORONTO, ON  —  (March 3,  2021) – Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the “Company” or “Claritas“) today announced that it has entered into a Strategic Collaboration Agreement (the Collaboration Agreement”) with the Salzman Group, Ltd. (“Salzman Group”), and is in the process of entering into similar agreements with other companies, to expedite the development of the Company’s breakthrough nitric oxide-releasing compound, R-107.

Continue reading Claritas (formerly Kalytera Therapeutics, Inc.) to Collaborate with Salzman Group and Other Companies to Accelerate Development of R-107 for Treatment of Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections →

Claritas (formerly Kalytera Therapeutics, Inc.) Announces Addition of Professor Salvatore Cuzzocrea, Ph.D. to the Company’s Board of Directors

Dr. Cuzzocrea’s Appointment Expands the Company’s Expertise in Field of Nitric Oxide Therapeutics

SAN FRANCISCO and TORONTO, March 05, 2021 — Claritas Pharmaceuticals, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the “Company” or “Claritas“) today announced the addition of Professor Salvatore Cuzzocrea, Ph.D. as an independent member of the Company’s board of directors (the “Board of Directors”), effective immediately.

Continue reading Claritas (formerly Kalytera Therapeutics, Inc.) Announces Addition of Professor Salvatore Cuzzocrea, Ph.D. to the Company’s Board of Directors →

Claritas (Formerly Kalytera Therapeutics) Cites Breakthrough Data by Massachusetts General Hospital and Others Demonstrating the Effectiveness of Nitric Oxide as a Potential Therapy for COVID-19 Infection and Validating the Potential of R-107 in this Indication

SAN FRANCISCO, CA and TORONTO, ON — (March 2, 2021) – Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the “Company” or “Claritas“) today announced that compelling data demonstrating that nitric oxide achieved viral clearance in severe and critical COVID-19 patients validates the potential of the Company’s proprietary nitric oxide releasing compound, R-107, as a therapy for coronavirus and COVID-19 infection.

Continue reading Claritas (Formerly Kalytera Therapeutics) Cites Breakthrough Data by Massachusetts General Hospital and Others Demonstrating the Effectiveness of Nitric Oxide as a Potential Therapy for COVID-19 Infection and Validating the Potential of R-107 in this Indication →

Claritas (formerly Kalytera Therapeutics) Announces Additional Program to Reduce the Rate and Spread of COVID-19 with Prophylactic R-107 Nasal Spray Designed to Provide Sustained Release of Nitric Oxide in the Nasal Cavities

SAN FRANCISCO and TORONTO, March 04, 2021 (GLOBE NEWSWIRE) — Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the “Company” or “Claritas“) today announced that it has initiated a second development program with R-107, the Company’s proprietary nitric oxide-releasing compound. The Company is currently developing R-107 as a therapy for vaccine-resistant COVID-19, influenza and other viral infections. The additional program that the Company is announcing today will develop R-107 as a nasal spray designed to be used prophylactically to prevent viral infections.

Continue reading Claritas (formerly Kalytera Therapeutics) Announces Additional Program to Reduce the Rate and Spread of COVID-19 with Prophylactic R-107 Nasal Spray Designed to Provide Sustained Release of Nitric Oxide in the Nasal Cavities →

Claritas Cites Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe COVID-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107

Study Demonstrated that Nitric Oxide Administered to Patients with Severe COVID-19 Pneumonia Significantly Improved Oxygen Levels 

SAN FRANCISCO, CA and TORONTO, ON — (July 26, 2021) – Claritas Pharmaceuticals, Inc.  (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas“) today announced that a recently published study led by clinicians at Royal Brompton & Harefield NHS Foundation Trust validates the potential of the Company’s proprietary nitric oxide releasing compound, R-107, as a potential therapy for coronavirus and COVID-19 infection. In the cited study, inhaled nitric oxide was seen to significantly improve oxygen levels administered in patients with severe COVID-19 pneumonia.

Continue reading Claritas Cites Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe COVID-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107 →

Claritas Anticipates Response from Australian Ethics Committee by February 18, 2022

Ethics Committee Approval is Final Step Prior to Enrollment of Claritas’ Phase 1 Clinical Study of R-107

SAN FRANCISCO, CA and TORONTO, ON — (February 9, 2022) – Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas“) today announced that the Australian Human Research Ethics Committee (HREC) will meet on February 16th to review the submission made by the Company for the Phase 1 clinical study of R-107. The Company expects to receive comments or approval from the HREC by February 18th. HREC approval is the final regulatory step prior to initiation of the study. Claritas will begin enrollment in the study immediately following receipt of HREC approval.

Continue reading Claritas Anticipates Response from Australian Ethics Committee by February 18, 2022 →